AN2 Therapeutics, Inc.
ANTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001880438
In the last 90 days, AN2 Therapeutics, Inc. insiders filed 1 open-market purchase and 5 sales; 66 institutions reported holding it in 13F filings for Q2 2026, worth $119.0M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by AN2 Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $11.6K in total
- Open-market sells
- 5 filings
- 3 insiders, $343.0K in total
- Insiders trading
- 4
- Net value
- −$331.4K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for AN2 Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Trenor Cameron C. III | Chief Medical Officer | 116,667 | Sep 16, 2026 | 1 |
| Readnour Robin Shane | Director | 624,765Indirect | Sep 11, 2026 | 5 |
| Williams Sarah Joanne | Principal Accounting Officer | 66,311 | Sep 4, 2026 | 4 |
| FitzPatrick Margaret M | Director | 10,708 | Sep 2, 2026 | 3 |
| Zakrzewski Joseph S | Director | 0Indirect | Aug 14, 2026 | 3 |
| Aziz Kabeer | Director | 59,106 | Jul 10, 2026 | 6 |
| Marks Gilbert Lynn | Director | 81,873 | Jul 10, 2026 | 6 |
| Martin Patricia A. | Director | 18,863 | Jul 10, 2026 | 6 |
| Eizen Joshua M | See Remarks | 206,554 | Jul 10, 2026 | 5 |
| Spigelman Melvin K | Director | – | Mar 23, 2026 | 2 |
| Wong Stephanie | Director | – | Mar 23, 2026 | 2 |
| Chanda Sanjay | Chief Development Officer | 118,823 | Mar 23, 2026 | 3 |
| Easom Eric | Chief Executive Officer | 368,630 | Mar 23, 2026 | 2 |
| Day Lucy | Chief Financial Officer | 118,363 | Mar 23, 2026 | 3 |
| Prior Stephen David | Chief Strategy Officer | 59,086 | Jan 7, 2026 | 2 |
| Leonard Braden Michael | 10% Owner | 3,017,432Indirect | Jun 16, 2025 | 0 |
| RA Capital Healthcare Fund LP | 10% Owner | 300,853Indirect | Aug 13, 2024 | 0 |
| Ra Capital Management, L.P. | 10% Owner | 300,853Indirect | Aug 13, 2024 | 0 |
| Kolchinsky Peter | 10% Owner | 300,853Indirect | Aug 13, 2024 | 0 |
| Shah Rajeev M. | 10% Owner | 300,853Indirect | Aug 13, 2024 | 0 |
| RA Capital Nexus Fund II, L.P. | 10% Owner | 300,853Indirect | Aug 13, 2024 | 0 |
| Eckburg Paul | Chief Medical Officer | 51,416 | Mar 29, 2024 | 0 |
| Krause Kevin Michael | Chief Strategy Officer | 31,914 | Mar 29, 2024 | 0 |
| Adjuvant Global Health Technology Fund, L.P. | 10% Owner | 377,542Indirect | Jan 18, 2024 | 0 |
| Adjuvant Global Health Technology Fund DE, L.P. | 10% Owner | 377,542Indirect | Jan 18, 2024 | 0 |
| Adjuvant Capital Management, LLC | 10% Owner | 377,542Indirect | Jan 18, 2024 | 0 |
| Adjuvant Capital GP, L.P. | 10% Owner | 377,542Indirect | Jan 18, 2024 | 0 |
| Nazak Michael Adrian | Chief Accounting Officer | – | Feb 17, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 27, 2024 (view filing) | Nov 27 | Same day | Zakrzewski Joseph SDirector | PPurchase | +2.00K | $1.40 | +$2.80K | +1.6%125.2K after | |
| Nov 27, 2024 (view filing) | Nov 26-27 | 1 day | Readnour Robin ShaneDirector | PPurchase | +75.0K | $1.41 | +$105.8K | +13.7%622.6K after | 4 lots |
| Dec 10, 2024 (view filing) | Dec 6-10 | 4 days | Readnour Robin ShaneDirector | PPurchase | +60.0K | $1.45 | +$86.8K | +10.1%652.6K after | 6 lots |
| Jan 7, 2025 (view filing) | Jan 3 | 4 days | Eizen Joshua MSee Remarks | SSale | −9.66K | $1.34 | −$12.9K | −7.6%116.7K after | |
| Jan 7, 2025 (view filing) | Jan 3 | 4 days | Prior Stephen DavidChief Strategy Officer | SSale | −2.03K | $1.34 | −$2.72K | −5.7%33.3K after | |
| Jan 7, 2025 (view filing) | Jan 3 | 4 days | Chanda SanjayChief Development Officer | SSale | −2.96K | $1.34 | −$3.96K | −9.0%29.8K after | |
| Jan 7, 2025 (view filing) | Jan 3 | 4 days | Day LucyChief Financial Officer | SSale | −2.96K | $1.34 | −$3.96K | −8.3%32.7K after | |
| May 29, 2025 (view filing) | May 28 | 1 day | FitzPatrick Margaret MDirector | PPurchase | +8.61K | $1.18 | +$10.2K | New position8.61K after | |
| May 30, 2025 (view filing) | May 28-30 | 2 days | Leonard Braden Michael10% Owner | SSale | −2.53M | $1.13 | −$2.87M | −44.0%3.22M after | 4 lots |
| Jun 3, 2025 (view filing) | Jun 2 | 1 day | Easom EricChief Executive Officer | PPurchase | +10.0K | $1.07 | +$10.7K | +4.1%256.4K after | |
| Jun 16, 2025 (view filing) | May 28 | 19 daysLate | Leonard Braden Michael10% Owner | SSale | −200.0K | $1.09 | −$218.0K | −6.2%3.02M after | |
| Nov 6, 2025 (view filing) | Nov 4 | 2 days | Prior Stephen DavidChief Strategy Officer | SSale | −765 | $1.14 | −$872.1 | −1.2%65.5K after | |
| Nov 6, 2025 (view filing) | Nov 4 | 2 days | Eizen Joshua MSee Remarks | SSale | −2.82K | $1.14 | −$3.21K | −1.6%177.4K after | |
| Jan 7, 2026 (view filing) | Jan 5-6 | 2 days | Eizen Joshua MSee Remarks | SSale | −24.9K | $1.00 | −$24.9K | −14.0%152.5K after | 2 lots |
| Jan 7, 2026 (view filing) | Jan 5-6 | 2 days | Chanda SanjayChief Development Officer | SSale | −9.25K | $1.01 | −$9.31K | −10.9%75.8K after | 2 lots |
| Jan 7, 2026 (view filing) | Jan 5-6 | 2 days | Prior Stephen DavidChief Strategy Officer | SSale | −6.46K | $1.00 | −$6.49K | −9.9%59.1K after | 2 lots |
| Jan 7, 2026 (view filing) | Jan 5-6 | 2 days | Day LucyChief Financial Officer | SSale | −8.81K | $1.01 | −$8.86K | −10.5%75.4K after | 2 lots |
| Mar 5, 2026 (view filing) | Mar 3 | 2 days | Williams Sarah JoannePrincipal Accounting Officer | SSale | −327 | $1.06 | −$346.62 | −0.5%66.8K after | |
| Jun 2, 2026 (view filing) | May 29 | 4 days | Williams Sarah JoannePrincipal Accounting Officer | SSale | −265 | $4.43 | −$1.17K | −0.4%66.6K after | |
| Jul 10, 2026 (view filing)6:15 PM ET | Jul 8 | 2 days | Eizen Joshua MSee Remarks | SSale | −5.95K | $4.17 | −$24.8K | −2.8%206.6K after | |
| Aug 19, 2026 (view filing)5:58 PM ET | Aug 17 | 2 days | Readnour Robin ShaneDirector | SSale | −35.4K | $6.01 | −$212.7K | −5.3%633.9K after | 2 lots10b5-1 |
| Sep 2, 2026 (view filing)6:43 PM ET | Sep 1 | 1 day | FitzPatrick Margaret MDirector | PPurchase | +2.10K | $5.53 | +$11.6K | +24.4%10.7K after | |
| Sep 4, 2026 (view filing)4:25 PM ET | Sep 1 | 3 daysLate | Williams Sarah JoannePrincipal Accounting Officer | SSale | −272 | $5.53 | −$1.50K | −0.4%66.3K after | |
| Sep 8, 2026 (view filing)7:42 PM ET | Sep 3-8 | 5 days | Readnour Robin ShaneDirector | SSale | −16.1K | $6.04 | −$97.3K | −2.5%625.4K after | 4 lots10b5-1 |
| Sep 11, 2026 (view filing)7:45 PM ET | Sep 9 | 2 days | Readnour Robin ShaneDirector | SSale | −1.11K | $6.02 | −$6.67K | −0.2%624.8K after | 2 lots10b5-1 |